July 2015 Vol. 3 No.7

Search Pubmed for articles by:
 

Original Research Article

Repositioning of Methotrexate to Cure Mutations of DYR, TYMS and PURA Gene, Bleomycin in the Treatment of Mutant DNA, TOPa, POLa, and RIR Genes

Anum Munir^1*, Shumaila Azam^1,2 and Sahar Fazal²

¹Department of Bioinformatics Government Post Graduate College Mandian, Abbottabad 22010, Pakistan.
²Department of Bioinformatics Muhammad Ali Jinnah University Islamabad 44000, Pakistan. Post Doc, Professor.

*Corresponding Author’s E-mail: anummunir786@yahoo.com
Tel.: +923348958178

Accepted July 06, 2015

Abstract

Osteosarcoma occurs because of germ line transformations of P53 gene and RB gene. At present doxorubicin, cisplatin and Methotrexate are viewed as dynamic drugs to cure osteosarcoma. Lymphoma grows because of neoplastic transformations of CD20, CD40, LMP gene, and B cells. Currently rituximab and Bleomycin are utilized as monoclonal antibodies against this ailment. Drug repositioning is new emerging phenomenon of reusing old drugs, protecting retired drugs and developing licenses to make lives easy. The primary objective of study was repositioning of methotrexate and Bleomycin to use in other diseases also. We found out interactions of both these drugs with several off targets, methotrexate showed strong interactions with DYR gene, Bleomycin demonstrated strong interactions with DNA, DNL1 and DNL3. After screening large amount of drugs which are used to cure mutations of those off target genes and proteins, compared their side effects and suggested that methotrexate and Bleomycin have fewer side effects as compared to other drugs which are used in same interacting targets. Both methotrexate and Bleomycin can be reposition to cure certain carcinomas and other diseases.

Keywords: Bleomycin, Interactions, Lymphoma, Methotrexate, Osteosar-coma, Repositioning